Shirakawa, Toshihiko
Nakashima, Yumiko
Watanabe, Satoshi
Harada, Sadatomo
Kinoshita, Mariko
Kihara, Toshiharu
Hamasaki, Yuko
Shishido, Seiichiro
Yoshiura, Koh-ichiro
Moriuchi, Hiroyuki
Dateki, Sumito
Funding for this research was provided by:
Japan Agency for Medical Research and Development (15gk0110012h0101)
Article History
Received: 12 December 2017
Accepted: 30 December 2017
First Online: 9 January 2018
Compliance with ethical standards
:
: Yuko Hamasaki belongs to a department endowed with sponsorship by Asahi Kasei Pharma Corporation, Novartis Pharma K.K., Chugai Pharmaceutical Co., and Astellas Pharma. The other authors have declared that no Conflict of interest exists.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the Institutional Review Board at Nagasaki University Graduate School of Biomedical Sciences at which the study was conducted (IRB approval number 151027331) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study.